Combiclav Lactating Cow Intramammary Suspension

Name:

 Combiclav Lactating Cow Intramammary Suspension

Category:

 Intramammaries

Region:

 United Kingdom

Combiclav Lactating Cow Intramammary Suspension is an off-white to cream suspension supplying 200 mg amoxicillin (as amoxicillin trihydrate Ph. Eur), 50 mg clavulanic acid (as potassium clavulanate Ph.Eur.) and 10 mg prednisolone Ph.Eur. per 3g syringe.

Combiclav Lactating Cow Intramammary Suspension is specially formulated for the treatment of bovine mastitis. It has a notably broad spectrum of bactericidal activity against the bacteria commonly found in the bovine udder. The prednisolone in Combiclav Lactating Cow Intramammary Suspension has an anti-inflammatory action which helps to reduce the potentially destructive swelling and inflammation associated with mastitis, without affecting the white cell response to infection.

In vitro, Combiclav Lactating Cow Intramammary Suspension is active against a wide range of clinically important bacteria, including the following organisms, which are commonly associated with bovine mastitis:

Staphylococci (including beta-lactamase producing strains).
Streptococci (including S. agalactiae, S. dysgalactiae and S. uberis).
A. pyogenes and other minor members of the Corynebacteria spp.
Escherichia coli (including beta-lactamase producing strains).

In addition, it is active in vitro against many less common udder pathogens including:

Bacillus cereus, Bacteroides (including beta-lactamase producing strains), Campylobacter spp, Klebsiellae and Pasteurellae.

Clinically, Combiclav Lactating Cow Intramammary Suspension has been shown to be an effective, routine treatment for mastitis in lactating cows. Cases responding successfully to treatment include infections with the following major pathogens:

Staphylococci (including beta-lactamase producing strains).
Streptococci (including S. agalactiae, S. dysgalactiae and S. uberis).
Escherichia coli (including beta-lactamase producing strains).

Combiclav Lactating Cow Intramammary Suspension should be administered at a dose rate of 3 syringes per infected quarter with a single syringe given every 12 hours. Use each syringe only once.

After milking, clean and disinfect the teat end thoroughly with surgical spirit. Insert the syringe nozzle into the teat orifice and apply gentle and continuous pressure until the entire suspension is released. The treated quarter(s) may be milked out at the next normal milking time, but the milk should be discarded.

Combined Therapy for the treatment of bovine mastitis. In the situation where systemic treatment as well as intramammary treatment is necessary, Combiclav Injection can be administered in combination with Combiclav Lactating Cow Intramammary Suspension using the following minimum treatment regime:

Milk for human consumption must not be taken from a cow during treatment. With cows milked twice daily, milk for human consumption may only be taken from 60 hours (i.e. at the 5th milking) after the last treatment.

Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 7 days from the last treatment.

With other milking routines, the basis of the veterinary surgeon’s advice should be that milk may be taken for human consumption only after the same period from the last treatment (e.g. with three times a day milking and the product administered twice per day, milk for human consumption may only be taken at the 8th milking).

During the course of treatment the situation should be reviewed frequently by close veterinary supervision.

Combined Therapy: When using Combiclav Lactating Cow Intramammary and Combiclav Injection in combination, animals must not be slaughtered for human consumption during treatment. Cows may not be slaughtered for human consumption until 42 days after the last treatment. Milk must not be taken for human consumption during treatment. Milk for human consumption may be taken only from cows after 60 hours from the last treatment of Combiclav Injection following the minimum posology regime as described in Dosage and Administration.

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.

Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations. Handle this product with great care to avoid exposure, taking all recommended precautions.

If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention. Wash hands after use.

Do not store above 25°C. Store out of the reach of children.

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

POM

Supplied in a low-density polyethylene syringe with cap, delivering 3 g of product.

DISTRIBUTED BY:
Norbrook Laboratories (GB) Limited
The Green
Great Corby
Carlisle
Cumbria, CA4 8LR

Resistance to many antibiotics is caused by bacterial beta-lactamase enzymes which destroy the antibiotic before it can act. The clavulanic acid in Combiclav Lactating Cow Intramammary Suspension counteracts this defence mechanism by inactivating the beta-lactamases, thus rendering the bacteria sensitive to amoxicillin's rapid bactericidal effect, at concentrations readily attainable in the udder.

Combiclav Lactating Cow Intramammary Suspension is effective against Klebsiella infections found in veterinary practice in vitro, but it is not indicated for cases involving Pseudomonas species.

Vm: 02000/4240
ML: 2000/01


FOR ANIMAL TREATMENT ONLY.